Table 3.

AKI risk in patients whose coagulopathy was induced by warfarin or dabigatran

Ref.	Type	Patient No.a	%WRNb	Mean INRc		Mean SCr increase, mg/dl		↑ CKD Progression	↑ Mortality in WRN
				WRN	No WRN	WRN	No WRN
Brodsky et al.1	R	49	37	4.91±3.1	4.21±1.3	0.61±0.44	0.04±0.19	Yes	ND
Brodsky et al.13	R	4006	20.5	4.44±2.46	4.15±2.15	1.13±1.01	0.09±0.56	Yes	Yes
Lim and Campbell30	P	150	63d	Mean ∆ 4.8±2.2e		NR	NR	NR	NR
An et al.31	R	1297	19.3	4.19±1.56	3.82±1.14	0.81±0.94	−0.05±0.29	Yes	Yes
Berger et al.32	R	25Wf	42	NR	NR	39.9±10g	NR	NR	Yes
		15Dh	53			NR	NR	NR	Yes

WRN, warfarin-related nephropathy; IRN, international normalized ratio; SCr, serum creatinine; R, retrospective; ND, not done; P, prospective; NR, not reported; W, warfarin; D, dabigatran.

^aNumber of patients with acute increase in INR>3.0 and SCr measured within 1 week of INR>3.0.

^bPercentage of patients with INR>3.0 who developed AKI on the basis of the AKIN criteria (see text). D-treated patients are reported as the percentage of patients with AKI (27).

^cAt the discovery of AKI.

^dThis study reported that 30.7% of the warfarin-treated patients developed AKI. However, of those with INR>3.0, 63% developed AKI. That is the value reported here, because it conforms to the criteria for WRN used in the other four studies.

^eThe INRs of the AKI and no AKI groups were not reported separately, but the mean difference between the group was reported as NS (P=0.34).

^fNumber of patients with coagulopathy attributed to warfarin therapy.

^gReported as percentage changes from baseline.

^hNumber of patients with coagulopathy attributed to D therapy.